165 related articles for article (PubMed ID: 7811561)
1. FDG-PET for predicting the prognosis of malignant lymphoma.
Okada J; Oonishi H; Yoshikawa K; Itami J; Uno K; Imaseki K; Arimizu N
Ann Nucl Med; 1994 Aug; 8(3):187-91. PubMed ID: 7811561
[TBL] [Abstract][Full Text] [Related]
2. The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis.
Okada J; Yoshikawa K; Imazeki K; Minoshima S; Uno K; Itami J; Kuyama J; Maruno H; Arimizu N
J Nucl Med; 1991 Apr; 32(4):686-91. PubMed ID: 2013808
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
Becherer A; Mitterbauer M; Jaeger U; Kalhs P; Greinix HT; Karanikas G; Pötzi C; Raderer M; Dudczak R; Kletter K
Leukemia; 2002 Feb; 16(2):260-7. PubMed ID: 11840293
[TBL] [Abstract][Full Text] [Related]
4. The use of PET-18FDG imaging in the clinical evaluation of head and neck lymphoma.
Walsh RM; Wong WL; Chevretton EB; Beaney RP
Clin Oncol (R Coll Radiol); 1996; 8(1):51-4. PubMed ID: 8688363
[TBL] [Abstract][Full Text] [Related]
5. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.
Moog F; Bangerter M; Diederichs CG; Guhlmann A; Kotzerke J; Merkle E; Kolokythas O; Herrmann F; Reske SN
Radiology; 1997 Jun; 203(3):795-800. PubMed ID: 9169707
[TBL] [Abstract][Full Text] [Related]
6. FDG-PET for the evaluation of tumor viability after anticancer therapy.
Okada J; Oonishi H; Yoshikawa K; Imaseki K; Uno K; Itami J; Arimizu N
Ann Nucl Med; 1994 May; 8(2):109-13. PubMed ID: 8074956
[TBL] [Abstract][Full Text] [Related]
7. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity.
Okada J; Yoshikawa K; Itami M; Imaseki K; Uno K; Itami J; Kuyama J; Mikata A; Arimizu N
J Nucl Med; 1992 Mar; 33(3):325-9. PubMed ID: 1740697
[TBL] [Abstract][Full Text] [Related]
8. FDG PET in the management of lymphoma: a clinical perspective.
Hoskin PJ
Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):449-51. PubMed ID: 11914880
[No Abstract] [Full Text] [Related]
9. [18F]fluorodeoxyglucose uptake in tumors: kinetic vs. steady-state methods with reference to plasma insulin.
Minn H; Leskinen-Kallio S; Lindholm P; Bergman J; Ruotsalainen U; Teräs M; Haaparanta M
J Comput Assist Tomogr; 1993; 17(1):115-23. PubMed ID: 8419418
[TBL] [Abstract][Full Text] [Related]
10. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose.
Lapela M; Leskinen S; Minn HR; Lindholm P; Klemi PJ; Söderström KO; Bergman J; Haaparanta M; Ruotsalainen U; Solin O; Joensuu H
Blood; 1995 Nov; 86(9):3522-7. PubMed ID: 7579459
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma.
Cremerius U; Fabry U; Neuerburg J; Zimny M; Bares R; Osieka R; Büll U
Nuklearmedizin; 2001 Feb; 40(1):23-30. PubMed ID: 11373935
[TBL] [Abstract][Full Text] [Related]
12. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer.
Minn H; Lapela M; Klemi PJ; Grénman R; Leskinen S; Lindholm P; Bergman J; Eronen E; Haaparanta M; Joensuu H
J Nucl Med; 1997 Dec; 38(12):1907-11. PubMed ID: 9430467
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas.
Dimitrakopoulou-Strauss A; Strauss LG; Goldschmidt H; Lorenz WJ; Maier-Borst W; van Kaick G
Eur J Nucl Med; 1995 May; 22(5):434-42. PubMed ID: 7641752
[TBL] [Abstract][Full Text] [Related]
14. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma.
de Wit M; Bumann D; Beyer W; Herbst K; Clausen M; Hossfeld DK
Ann Oncol; 1997; 8 Suppl 1():57-60. PubMed ID: 9187431
[TBL] [Abstract][Full Text] [Related]
15. High [18F]FDG uptake in primary cerebral lymphoma: a PET study.
Kuwabara Y; Ichiya Y; Otsuka M; Miyake Y; Gunasekera R; Hasuo K; Masuda K; Takeshita I; Fukui H
J Comput Assist Tomogr; 1988; 12(1):47-8. PubMed ID: 3257221
[TBL] [Abstract][Full Text] [Related]
16. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT.
Newman JS; Francis IR; Kaminski MS; Wahl RL
Radiology; 1994 Jan; 190(1):111-6. PubMed ID: 8259386
[TBL] [Abstract][Full Text] [Related]
17. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma.
Kostakoglu L; Leonard JP; Kuji I; Coleman M; Vallabhajosula S; Goldsmith SJ
Cancer; 2002 Feb; 94(4):879-88. PubMed ID: 11920454
[TBL] [Abstract][Full Text] [Related]
18. Uncoupling of fatty acid and glucose metabolism in malignant lymphoma: a PET study.
Nuutinen J; Minn H; Bergman J; Haaparanta M; Ruotasalainen U; Laine H; Knuuti J
Br J Cancer; 1999 May; 80(3-4):513-8. PubMed ID: 10408861
[TBL] [Abstract][Full Text] [Related]
19. Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxyglucose positron emission tomography.
Rosenfeld SS; Hoffman JM; Coleman RE; Glantz MJ; Hanson MW; Schold SC
J Nucl Med; 1992 Apr; 33(4):532-6. PubMed ID: 1552337
[TBL] [Abstract][Full Text] [Related]
20. [Positron emission tomography (PET) in diagnosis and therapy planning of malignant lymphoma].
Dimitrakopoulou-Strauss A; Strauss LG; Goldschmidt H; Hegenbart U; Irngartinger G; Oberdorfer F; van Kaick G
Radiologe; 1997 Jan; 37(1):74-80. PubMed ID: 9157479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
